newsfilter
← Latest News
GlobeNewswire·

HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

  • Human studies indicate the TGF-β trap & IL-15 fusion promotes expansion of progenitor CD8+ T cells & NK cells while showing clinical benefit & tolerability in cancer patients.
  • The fusion demonstrated activity against HIV-1 & bronchopulmonary dysplasia in stringent animal models.
  • HCW Biologics incorporated the TGF-β/IL-15 moiety into its second-generation T Cell Engager (TCE) & Immune Checkpoint Inhibitor (ICI) programs using the TRBC platform.
  • Lead TCE candidate HCW11-018b combines the TGF-β/IL-15 fusion with a tissue-factor-targeting BiTE to enhance immune stimulation & counter immunosuppression in solid tumors.
  • Lead ICI candidate HCW11-040 combines pembrolizumab with the TGF-β/IL-15 moiety, showing superior immune activation & cytotoxicity compared to pembrolizumab in preclinical studies.
  • Both HCW11-018b & HCW11-040 are at the IND-enabling stage, with clinical studies planned to initiate in 2027.
  • HCW Biologics is a clinical-stage biopharmaceutical company focused on fusion immunotherapeutics for autoimmune diseases, cancer, & senescence-associated dysplasia.
  • The company plans to advance its pipeline through business development & licensing agreements for proprietary molecules.